Molecular basis of inherited colorectal carcinomas in the Macedonian population: An update

1 Lorans M, Dow E, Macrae FA, Winship IM, Buchanan DD. Update on hereditary colorectal cancer: Improving the clinical utility of multigene panel testing. Clin Colorectal Cancer. 2018; 17(2): e293-e305. Lorans M Dow E Macrae FA Winship IM Buchanan DD Update on hereditary colorectal cancer: Improving the clinical utility of multigene panel testing Clin Colorectal Cancer 2018 172 e293 e30510.1016/j.clcc.2018.01.00129454559Search in Google Scholar

2 Loomans-Kropp HA, Umar A. Cancer prevention and screening: The next step in the era of precision medicine. NPJ Precis Oncol. 2019; 3: 3. Loomans-Kropp HA Umar A Cancer prevention and screening: The next step in the era of precision medicine NPJ Precis Oncol 2019 3 310.1038/s41698-018-0075-9634990130701196Search in Google Scholar

3 Boland PM, Yurgelun MB, Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018; 68(3): 217-231. Boland PM Yurgelun MB Boland CR Recent progress in Lynch syndrome and other familial colorectal cancer syndromes CA Cancer J Clin 2018 683 217 23110.3322/caac.21448598069229485237Search in Google Scholar

4 Valle L. Genetic predisposition to colorectal cancer: Where we stand and future perspectives. World J Gastroenterol. 2014; 20(29): 9828-9849. Valle L Genetic predisposition to colorectal cancer: Where we stand and future perspectives World J Gastroenterol 2014 2029 9828 984910.3748/wjg.v20.i29.9828412336625110415Search in Google Scholar

5 Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, et al. Colorectal Transdisciplinary (CORECT) Study; Genetic and Epidemiology of Colorectal Cancer Consortium (GECCO). A model to determine colorectal cancer risk using common genetic susceptibility loci. Gastroenterology. 2015; 148(7): 1330-1339.e14. Hsu L Jeon J Brenner H Gruber SB Schoen RE Berndt SI Colorectal Transdisciplinary (CORECT) Study; Genetic and Epidemiology of Colorectal Cancer Consortium (GECCO). A model to determine colorectal cancer risk using common genetic susceptibility loci Gastroenterology 2015 1487 1330 133910.1053/j.gastro.2015.02.010444619325683114Search in Google Scholar

6 Hiljadnikova-Bajro M, Josifovski T, Panovski M, Dimovski AJ. A novel germline MLH1 mutation causing Lynch Syndrome in patients from the Republic of Macedonia. Croat Med J. 2012; 53(5): 496-501. Hiljadnikova-Bajro M Josifovski T Panovski M Dimovski AJ A novel germline MLH1 mutation causing Lynch Syndrome in patients from the Republic of Macedonia Croat Med J 2012 535 496 50110.3325/cmj.2012.53.496349046023100212Search in Google Scholar

7 Stefanovska AM, Josifovski T, Panovski M, Jasar D, Zografski G, Efremov GD, et al. Molecular characterization of familial adenomatous polyposis in the Republic of Macedonia. Balkan J Med Genet. 2004; 7(1&2): 33-40. Stefanovska AM Josifovski T Panovski M Jasar D Zografski G Efremov GD Molecular characterization of familial adenomatous polyposis in the Republic of Macedonia Balkan J Med Genet 2004 71&2 33 40Search in Google Scholar

8 Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009; 15(47): 5907-5915. Zavoral M Suchanek S Zavada F Dusek L Muzik J Seifert B Colorectal cancer screening in Europe World J Gastroenterol 2009 1547 5907 591510.3748/wjg.15.5907279517720014454Search in Google Scholar

9 Pérez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM, Guillén C, et al Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn. 2010; 12(4): 498-504. Pérez-Carbonell L Alenda C Payá A Castillejo A Barberá VM Guillén C Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome J Mol Diagn 2010 124 498 50410.2353/jmoldx.2010.090212289363520489114Search in Google Scholar

10 Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. Wang K Li M Hakonarson H ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data Nucleic Acids Res 2010 3816e16410.1093/nar/gkq603293820120601685Search in Google Scholar

11 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405-424. Richards S Aziz N Bale S Bick D Das S Gastier-Foster J Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet Med 2015 175 405 42410.1038/gim.2015.30454475325741868Search in Google Scholar

12 Ma H, Difazio S. An efficient method for purification of PCR products for sequencing. BioTechniques. 2008; 44(7): 921-923. Ma H Difazio S An efficient method for purification of PCR products for sequencing BioTechniques 2008 447 921 92310.2144/00011280918533902Search in Google Scholar

13 Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J Clin Oncol. 2015; 33(5): 426-432. Chubb D Broderick P Frampton M Kinnersley B Sherborne A Penegar S Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing J Clin Oncol 2015 335 426 43210.1200/JCO.2014.56.568925559809Search in Google Scholar

14 Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017; 3(4): 464-471. Pearlman R Frankel WL Swanson B Zhao W Yilmaz A Miller K Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer JAMA Oncol 2017 34 464 47110.1001/jamaoncol.2016.5194556417927978560Search in Google Scholar

15 Liu B, Parsons RE, Hamilton SR, Petersen GM, Lynch HT, Watson P, et al hMSH2 Mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res. 1994; 54(17): 4590-4594. Liu B Parsons RE Hamilton SR Petersen GM Lynch HT Watson P hMSH2 Mutations in hereditary nonpolyposis colorectal cancer kindreds Cancer Res 1994 5417 4590 4594Search in Google Scholar

16 Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007; 44(6): 353-362. Vasen HF Moslein G Alonso A Bernstein I Bertario L Blanco I Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) J Med Genet 2007 446 353 36210.1136/jmg.2007.048991274087717327285Search in Google Scholar

17 Khoo SK, Giraud S, Kahnoski K, Chen J, Motorna O, Nickolov R, et al Clinical and genetic studies of Birt-Hogg-Dubé syndrome. J Med Genet. 2002; 39(12): 906-912. Khoo SK Giraud S Kahnoski K Chen J Motorna O Nickolov R Clinical and genetic studies of Birt-Hogg-Dubé syndrome J Med Genet 2002 3912 906 91210.1136/jmg.39.12.906175721912471204Search in Google Scholar

18 Shin JH, Shin YK, Ku JL, Jeong SY, Hong SH, Park SY, et al Mutations of the Birt-Hogg-Dube (BHD) gene in sporadic colorectal carcinomas and colorectal carcinoma cell lines with microsatellite instability. J Med Genet. 2003; 40(5):364-367. Shin JH Shin YK Ku JL Jeong SY Hong SH Park SY Mutations of the Birt-Hogg-Dube (BHD) gene in sporadic colorectal carcinomas and colorectal carcinoma cell lines with microsatellite instability J Med Genet 2003 405364 36710.1136/jmg.40.5.364173547112746401Search in Google Scholar

19 Nahorski MS, Lim DHK, Martin L, Gille JJP, McKay K, Rehal PK, et al Investigation of the Birt-Hogg-Dubé tumour suppressor gene (<em>FLCN</em>) in familial and sporadic colorectal cancer. J Med Genet. 2010; 47(6): 385-390. Nahorski MS Lim DHK Martin L Gille JJP McKay K Rehal PK Investigation of the Birt-Hogg-Dubé tumour suppressor gene (<em>FLCN</em>) in familial and sporadic colorectal cancer J Med Genet 2010 476 385 39010.1136/jmg.2009.07330420522427Search in Google Scholar

20 Kashiwada T, Shimizu H, Tamura K, Seyama K, Horie Y, Mizoo A. Birt-Hogg-Dube syndrome and familial adenomatous polyposis: An association or a coincidence? Intern Med. 2012; 51(13): 1789-1792. Kashiwada T Shimizu H Tamura K Seyama K Horie Y Mizoo A Birt-Hogg-Dube syndrome and familial adenomatous polyposis: An association or a coincidence? Intern Med 2012 5113 1789 179210.2169/internalmedicine.51.723922790147Search in Google Scholar

21 Stoffel EM, Koeppe E, Everett J, Ulintz P, Kiel M, Osborne J, et al Germline genetic features of young individuals with colorectal cancer. Gastroenterology. 2018; 154(4): 897-905.e1. Stoffel EM Koeppe E Everett J Ulintz P Kiel M Osborne J Germline genetic features of young individuals with colorectal cancer Gastroenterology 2018 1544 897 90510.1053/j.gastro.2017.11.004584742629146522Search in Google Scholar

22 Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, et al NCCN Guidelines insights: Genetic/familial high-risk assessment: Colorectal, Version 2.2019. J Natl Compr Canc Netw. 2019; 17(9): 1032-1041. doi: 10.6004/jnccn.2019.0044. Gupta S Provenzale D Llor X Halverson AL Grady W Chung DC NCCN Guidelines insights: Genetic/familial high-risk assessment: Colorectal, Version 2.2019 J Natl Compr Canc Netw 2019 179 1032 1041 10.6004/jnccn.2019.004431487681Open DOISearch in Google Scholar

23 Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, et al Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype. Cancer Cell. 2019; 35(2): 256-266. e5.(?) Grolleman JE de VoerRM Elsayed FA Nielsen M Weren RDA Palles C Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype Cancer Cell 2019 352 256 266 e5.(?)10.1016/j.ccell.2018.12.01130753826Search in Google Scholar

24 Valle L, de Voer RM, Goldberg Y, Sjursen W, Forsti A, Ruiz-Ponte C, et al Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med. 2019; 69:10-26. doi: 10.1016/j.mam.2019.03.001. Valle L de VoerRM Goldberg Y Sjursen W Forsti A Ruiz-Ponte C Update on genetic predisposition to colorectal cancer and polyposis Mol Aspects Med 2019 6910 26 10.1016/j.mam.2019.03.00130862463Open DOISearch in Google Scholar

25 Blount J, Prakash A. The changing landscape of Lynch syndrome due to PMS2 mutations. Clin Genet. 2018; 94(1): 61-69. Blount J Prakash A The changing landscape of Lynch syndrome due to PMS2 mutations Clin Genet 2018 941 61 6910.1111/cge.13205599563729286535Search in Google Scholar

26 Pino MS, Mino-Kenudson M, Wildemore BM, Ganguly A, Batten J, Sperduti I, et al Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn. 2009; 11(3): 238-247. Pino MS Mino-Kenudson M Wildemore BM Ganguly A Batten J Sperduti I Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas J Mol Diagn 2009 113 238 24710.2353/jmoldx.2009.080142267134119324997Search in Google Scholar

27 Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, et al Molecular and clinical characteristics of MSH6 variants: An analysis of 25 index carriers of a germline variant. Am J Hum Genet. 2002; 70(1): 26-37. Berends MJ Wu Y Sijmons RH Mensink RG van der SluisT Hordijk-Hos JM Molecular and clinical characteristics of MSH6 variants: An analysis of 25 index carriers of a germline variant Am J Hum Genet 2002 701 26 3710.1086/33794438489611709755Search in Google Scholar

28 Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, et al Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology. 2015; 149(3):604-613.e20. Yurgelun MB Allen B Kaldate RR Bowles KR Judkins T Kaushik P Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome Gastroenterology 2015 1493604 61310.1053/j.gastro.2015.05.006455053725980754Search in Google Scholar

29 Reilly NM, Novara L, Di Nicolantonio F, Bardelli A. Exploiting DNA repair defects in colorectal cancer. Mol Oncol. 2019; 13(4): 681-700. Reilly NM Novara L Di NicolantonioF Bardelli A Exploiting DNA repair defects in colorectal cancer Mol Oncol 2019 134 681 70010.1002/1878-0261.12467644192530714316Search in Google Scholar

30 AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T, et al Inherited DNA-repair defects in colorectal cancer. Am J Hum Genet. 2018; 102(3): 401-414. AlDubayan SH Giannakis M Moore ND Han GC Reardon B Hamada T Inherited DNA-repair defects in colorectal cancer Am J Hum Genet 2018 1023 401 41410.1016/j.ajhg.2018.01.018598528029478780Search in Google Scholar

31 Nielsen FC, van Overeem Hansen T, Sørensen CS. Hereditary breast and ovarian cancer: New genes in confined pathways. Nat Rev Cancer. 2016; 16(9): 599-612. Nielsen FC van Overeem HansenT Sørensen CS Hereditary breast and ovarian cancer: New genes in confined pathways Nat Rev Cancer 2016 169 599 61210.1038/nrc.2016.7227515922Search in Google Scholar

32 Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2019; 23(1): 239-254.e6. Knijnenburg TA Wang L Zimmermann MT Chambwe N Gao GF Cherniack AD Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas Cell Rep 2019 231 239 25410.1016/j.celrep.2018.03.076596150329617664Search in Google Scholar

33 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015; 373(18): 1697-1708. Mateo J Carreira S Sandhu S Miranda S Mossop H Perez-Lopez R DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med 2015 37318 1697 170810.1056/NEJMoa1506859Search in Google Scholar

34 Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet. 2010; 376(9737): 235-244. Tutt A Robson M Garber JE Domchek SM Audeh MW Weitzel JN Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial Lancet 2010 3769737 235 24410.1016/S0140-6736(10)60892-6Search in Google Scholar

35 Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, Arbeloa PD, et al Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: Results from the Know Your Tumor Program. JCO Precision Oncology. 2019; 37:(4 Suppl): 191. Pishvaian MJ Blais EM Brody JR Rahib L Lyons E Arbeloa PD Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: Results from the Know Your Tumor Program JCO Precision Oncology 2019 374 Suppl 19110.1200/PO.19.0011535100730Search in Google Scholar